Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Ovarian Neoplasms

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 23 articles: HTML format

Single Articles

May 2023
1. RAY-COQUARD I, Leary A, Pignata S, Cropet C, et al
   Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
   Ann Oncol. 2023 May 19:S0923-7534(23)00686-5. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   December 2022
2. LOVEDAY C, Garrett A, Law P, Hanks S, et al
   Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.
   Ann Oncol. 2022;33:1318-1327.
   PubMed     Abstract available
   
   
   November 2022
3. LABIDI-GALY SI, Rodrigues M, Sandoval JL, Kurtz JE, et al
   Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
   Ann Oncol. 2022 Nov 28:S0923-7534(22)04733-0. doi: 10.1016/j.annonc.2022.
   PubMed     Abstract available
   
   
   October 2022
4. SESSA C, Balmana J, Bober SL, Cardoso MJ, et al
   Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
   Ann Oncol. 2022 Oct 19. pii: S0923-7534(22)04193.
   PubMed    
   
   
   August 2022
5. KRISTELEIT RS, Moore K
   Life after SOLO-2: Is Olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi) resistant, recurrent ovarian cancer?
   Ann Oncol. 2022 Aug 11. pii: S0923-7534(22)03867.
   PubMed    
   
   
   June 2022
6. FRENEL JS, Kim JW, Aryal N, Asher R, et al
   Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
   Ann Oncol. 2022 Jun 27. pii: S0923-7534(22)01740.
   PubMed     Abstract available
   
   
   April 2022
7. COLEMAN RL
   For Ovarian Cancer PARPi maintenance therapy: more is better, right?
   Ann Oncol. 2022 Apr 7. pii: S0923-7534(22)00681.
   PubMed    
   
   
   February 2022
8. FRANCIS KE, Kim SI, Friedlander M, Gebski V, et al
   The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
   Ann Oncol. 2022 Feb 24. pii: S0923-7534(22)00338.
   PubMed     Abstract available
   
   
   January 2022
9. DALMARTELLO M, La Vecchia C, Bertuccio P, Boffetta P, et al
   European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
   Ann Oncol. 2022 Jan 13. pii: S0923-7534(21)04881.
   PubMed     Abstract available
   
   
   
10. MOORE KN, du Bois A
    Homologous recombination deficiency testing in first-line ovarian cancer.
    Ann Oncol. 2022 Jan 8. pii: S0923-7534(22)00004.
    PubMed    
    
    
    November 2021
11. VERGOTE I, Gonzalez-Martin A, Ray-Coquard I, Harter P, et al
    European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04828.
    PubMed     Abstract available
    
    
    August 2021
12. MARTIN JE, Khalife-Hachem S, Grinda T, Kfoury M, et al
    Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
    Ann Oncol. 2021;32:1046-1048.
    PubMed    
    
    
    July 2021
13. COLOMBO N, Ledermann JA
    Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines.
    Ann Oncol. 2021 Jul 14. pii: S0923-7534(21)02182.
    PubMed    
    
    
    
14. DI VINCENZO A, Andrisani A, Vettor R, Rossato M, et al
    Estrogen and COVID-19: friend or foe?
    Ann Oncol. 2021;32:933-934.
    PubMed    
    
    
    June 2021
15. MIRZA MR, Coleman RL, Gonzalez-Martin A, Moore KN, et al
    Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].
    Ann Oncol. 2021 Jun 2. pii: S0923-7534(21)02020.
    PubMed    
    
    
    March 2021
16. BAERT T, Ferrero A, Sehouli J, O Donnell DM, et al
    The Systemic Treatment of Recurrent Ovarian Cancer revisited.
    Ann Oncol. 2021 Mar 3. pii: S0923-7534(21)00155.
    PubMed     Abstract available
    
    
    
17. MOORE KN, Oza AM, Colombo N, Oaknin A, et al
    Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
    Ann Oncol. 2021 Mar 2. pii: S0923-7534(21)00157.
    PubMed     Abstract available
    
    
    January 2021
18. MONTOPOLI M, Zorzi M, Cocetta V, Prayer-Galetti T, et al
    Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy.
    Ann Oncol. 2021 Jan 29. pii: S0923-7534(21)00097.
    PubMed    
    
    
    
19. WU XH, Zhu JQ, Yin RT, Yang JX, et al
    Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase 3 trial.
    Ann Oncol. 2021 Jan 13. pii: S0923-7534(21)00008.
    PubMed     Abstract available
    
    
    
20. TOBALINA L, Armenia J, Irving E, O'Connor MJ, et al
    A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
    Ann Oncol. 2021;32:103-112.
    PubMed     Abstract available
    
    
    December 2020
21. PILIE PG, George A, Yap TA
    Patient selection biomarker strategies for PARP inhibitor therapy.
    Ann Oncol. 2020;31:1603-1605.
    PubMed    
    
    
    September 2020
22. MILLER RE, Leary A, Scott CL, Serra V, et al
    ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    Ann Oncol. 2020 Sep 28. pii: S0923-7534(20)42164.
    PubMed     Abstract available
    
    
    February 2020
23. WAKS AG, Cohen O, Kochupurakkal B, Kim D, et al
    Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: